PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Luoxin Pharmaceutical (SHANGHAI) Co., Ltd.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Luoxin ranks #48,484 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#48,484
of 49,997 US assignees by volume
18th percentile
by Innovation Score (25.7/100)
13.4
avg claims per patent
+300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R48484 · Foreign Corporation #48,484 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #48,484/49,997
  • PHOTO-FINISH Lumidigm
  • CPC-NARROW A61P · 4 areas
  • INNOV-THIN 25.7/100
  • CLAIMS-RICH 13.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lumidigm, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Luoxin’s 25.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Luoxin

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Luoxin's Innovation Score is 25.7/100 (18th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Luoxin?

Each dot is one of Luoxin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Luoxin’s own 13.4 claims/patent is ABOVE the 13.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Luoxin vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 0102030 Granted patents (volume) Avg claims / patent Lumidigm, Inc. - 5, 26.2LumidigmLumineq OY - 5, 16Lumineq OYLuneau Technology Operations - 5, 13Luneau Technology…Luonnonvarakeskus - 5, 16.6LuonnonvarakeskusLuoyang Steelart Office Furniture Co., Ltd - 5, 1Luoyang Steelart…Lusospace, Projectos Engenharia LDA - 5, 10.6Lusospace Project…Luther Systems US Incorporated - 5, 22Luther Systems US…Lutian Machinery Co., Ltd. - 5, 2.4Lutian MachineryLuoxin Pharmaceutical (SHANGHAI) Co., Ltd. - 5, 13.4Luoxin Pharmaceut…
Luoxin vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Luoxin's grants concentrate

Luoxin Pharmaceutical (SHANGHAI) Co., Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, Luoxin sits between Lumidigm, Inc. and Lutian Machinery Co., Ltd..

Luoxin's three-year grant acceleration

Luoxin Pharmaceutical (SHANGHAI) Co., Ltd. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Luoxin's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Luoxin holds 5 patents at rank #48,379, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Luoxin

By rank, the assignees closest to #48,379 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Luoxin's primary technology class.

Luoxin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 18th percentile higher than 18% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1 20192020202120232024 1
USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Luoxin Pharmaceutical (SHANGHAI) Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 1 20.0%
2020 1 20.0%
2021 1 20.0%
2023 1 20.0%
2024 1 20.0%

Which technologies does Luoxin Pharmaceutical (SHANGHAI) Co., Ltd. patent most?

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Luoxin Pharmaceutical (SHANGHAI) Co., Ltd.'s patent record in context - here's where to go next.

  • Luoxin Pharmaceutical (SHANGHAI) Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #48,484 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Luoxin Pharmaceutical (SHANGHAI) Co., Ltd. against Lumidigm, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 25.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.